Gilead has plans for a rapid launch in the United States as well as a wider rollout of the drug in collaboration with global ...

The US Food and Drug Administration on Wednesday approved Gilead Sciences’ twice-yearly injection to prevent HIV - a move the ...

Lenacapavir belongs to a new class of antiretrovirals known as capsid inhibitors. In large-scale clinical trials conducted ...

The drug, called Lenacapavir, nearly eliminated new infections in two groundbreaking studies of people at high risk, better ...

The FDA has approved Gilead’s long-anticipated HIV prevention shot, Yeztugo, offering a twice-a-year alternative to daily ...